Why the study?
Does genetic screening identify underlying mutations in patients with acquired Long QT Syndrome?
Does genetic screening identify underlying mutations in patients with acquired Long QT Syndrome?
Genetic mutations, particularly in KCNH2, are present in 28% of patients with acquired Long QT Syndrome, and a simple clinical scoring system can help identify those most likely to carry a mutation to improve cost-effectiveness of genetic testing.
Answers are grounded in this paper and cite their sources.
Clinicians should consider genetic predisposition in acquired LQTS; leaves open prospective validation of screening criteria.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hideki Itoh (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: